• Our mission

    Our mission is to be a leader in establishing minimally-invasive transcatheter heart valve implantation devices to treat valvular heart disease. Our safe and intuitive aortic heart valve replacement systems alleviate the burden of disease of high-risk patients suffering from severe aortic stenosis. Our devices give physicians greater control during delicate surgical interventions, and result in superb patient outcomes.

    Our mission
  • ACURATE

    Delivery Systems

    Symetis has developed exceptionally easy to use, intuitive transcatheter delivery systems with a flexible shaft and ergonomic design that allow for a controlled, sheathless, 2-step implantation. The systems’ intelligent design results in a short learning curve for physicians, and safe procedures for patients.

    ACURATE Delivery Systems
  • ACURATE TA

    Transcatheter aortic bioprosthesis

    The ACURATE TA transapical aortic bioprosthesis consists of three non-coronary native porcine leaflets attached to a self-expanding nitinol stent and a PET skirt sutured onto the inner and the outer surface of the stent. It is self-seating and self-sealing, allows for optimal positioning of the valve, and reduces paravalvular leak.

    ACURATE TA
  • ACURATE neo / TF

    Transcatheter aortic bioprosthesis

    The ACURATE neo™ transfemoral aortic bioprosthesis is composed of a porcine pericardial tissue valve sutured within a self-expanding nitinol stent covered by a pericardial skirt on the outer and inner surface of the stent body. ACURATE neo is self-seating and self-sealing, allows for optimal positioning of the valve, and reduces paravalvular leak.

    ACURATE neo/TF

latest news

  • September 12, 2014

    Symetis receives CE Mark approval for transfemoral transcatheter aortic heart valve system ACURATE neo™, and launches product with first commercial implantations

    Read more

  • April 03, 2014

    Symetis ACURATE TA™ confirms superior results in post-market registry.

    Read more

  • October 28, 2013

    Symetis Announces a Symbolic Milestone: the 1000th Patient implanted with ACURATE TA™.

    Read more   |  Voir le PDF en Français Ansicht PDF in German

  • September 26, 2013

    Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI.

    Read more

  • August 12, 2013

    Symetis announces successful, first time implantation of its ACURATE TA™ and ACURATE TF™ TAVI systems in Japan.

    Read more

  • October 22, 2012

    Symetis ACURATE TF™ FIM Trial Completed.

    Read more

next events

Clinical results

The success of Symetis is due to our strong and continuing investment in R&D and feedback from physicians, during every step of the development process. This philosophy has enabled us to design and manufacture products that truly reflect the requirements of our clinical partners.

ACURATE TA™ CE Mark Trial - Download

The SAVI Registry - Download

ACURATE TF™ FIM - Download